Histamine Phosphate
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB05381 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 14 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | bulbar polio | KG + DL |
| 2 | 5q35 microduplication syndrome | KG + DL |
| 3 | neuralgic amyotrophy | KG + DL |
| 4 | spondyloarthropathy | KG + DL |
| 5 | amyotrophic neuralgia | KG + DL |
| 6 | hypotrichosis simplex of the scalp | KG + DL |
| 7 | myelodysplastic/myeloproliferative disease | KG + DL |
| 8 | diffuse alopecia areata | KG + DL |
| 9 | congenital hypotrichosis milia | KG + DL |
| 10 | primary cutaneous T-cell non-Hodgkin lymphoma | KG + DL |
| 11 | acute lymphoblastic/lymphocytic leukemia | KG + DL |
| 12 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | KG + DL |
| 13 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | KG + DL |
| 14 | fibromatosis, gingival | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.